Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Chemicals and Drugs (2)
- Food and Drug Law (2)
- Intellectual Property Law (2)
- Medicine and Health Sciences (2)
- Administrative Law (1)
-
- Agriculture Law (1)
- Amino Acids, Peptides, and Proteins (1)
- Biological Engineering (1)
- Biomedical Devices and Instrumentation (1)
- Biomedical Engineering and Bioengineering (1)
- Biotechnology (1)
- Engineering (1)
- Insurance Law (1)
- Life Sciences (1)
- Litigation (1)
- Medical Jurisprudence (1)
- Molecular, Cellular, and Tissue Engineering (1)
- Other Biomedical Engineering and Bioengineering (1)
- Pharmacology, Toxicology and Environmental Health (1)
- Pharmacy and Pharmaceutical Sciences (1)
- Torts (1)
- Institution
Articles 1 - 4 of 4
Full-Text Articles in Health Law and Policy
The Fda Sends Smoke Signals To Big Tobacco: Will The Fda Suffer Backlash, Will Alcohol Be Regulated Next, And Will The Health Of Americans Prevail?, Angela Turriciano
The Fda Sends Smoke Signals To Big Tobacco: Will The Fda Suffer Backlash, Will Alcohol Be Regulated Next, And Will The Health Of Americans Prevail?, Angela Turriciano
Pepperdine Law Review
No abstract provided.
Incentivizing The Utilization Of Pharmacogenomics In Drug Development, Valerie Gutmann Koch
Incentivizing The Utilization Of Pharmacogenomics In Drug Development, Valerie Gutmann Koch
Journal of Health Care Law and Policy
No abstract provided.
A Vaccine Approach To The Reverse Payment Illness, Scott Bergeson
A Vaccine Approach To The Reverse Payment Illness, Scott Bergeson
Richmond Journal of Law & Technology
Big Brand Name develops and files a patent for a drug that kills bacteria in an innovative way. The drug is groundbreaking and potentially marketable, so Big Brand Name incurs the enormous cost (estimated at $868 million) and time of drug discovery research and safety determinations of clinical trials to bring the drug to market. Small Generic Company wants to sell the same drug but must wait until Big Brand Name’s patent expires or, in the alternative, Small Generic Company can file an Abbreviated New Drug Application (“ANDA”) with the FDA and allege Big Brand Name’s patent is invalid or …
A Thousand Tiny Pieces: The Federal Circuit’S Fractured Myriad Ruling, Lessons To Be Learned, And The Way Forward, Jonathan R. K. Stroud
A Thousand Tiny Pieces: The Federal Circuit’S Fractured Myriad Ruling, Lessons To Be Learned, And The Way Forward, Jonathan R. K. Stroud
IP Theory
No abstract provided.